All News

Every treatment bag should include an unlimited supply of humor. Stuff will happen. It’ll be hard, but you may learn to laugh about it later, like I did.

CURE spoke with an expert about the potential positive effects of psilocybin-assisted psychotherapy.

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.

Losing my hair after chemo was devastating, and I struggled to accept how it changed my appearance and self-image.

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in locally advanced hepatocellular carcinoma.

2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming experience and a fundraising walk.

CBD consumption was safe but did not have a statistically significant reduction in scan-related anxiety versus placebo for patients with breast cancer.

18F-DOPA PET−guided, dose-escalated, hypofractionated proton beam therapy led to improved OS in older patients with newly diagnosed glioblastoma.

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic malignancies.

After surviving colon cancer, I reflect on how the lessons from my journey transformed my life and guide me to embrace its beauty.

Veliparib plus temozolomide did not significantly extend overall survival in patients with newly diagnosed, MGMT-hypermethylated glioblastoma.

Dr. Richard “Rick" Winneker discussed advice that he would provide to patients faced with a myeloproliferative neoplasm diagnosis.

Emily Armstrong, Rose Sawyer and Ruth Cummings, oncology nurses, are recognized for their dedication, expertise and patient advocacy at Denver Health.

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell lung cancer.

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with recurrent H3 K27M-mutant diffuse glioma.

Ann Graham of MIB Agents discussed some of the challenges adolescent and young adult patients deal with after cancer diagnoses.

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

I've learned to embrace the changing nature of my body as I age, accepting the challenges and finding gratitude in each day.

From tennis star Gabriela Dabrowski sharing details of her breast cancer journey to Greg Gumbel and Linda Lavin dying, here is the latest cancer news.

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

An expert explained recent findings from a study of pregnant women with breast cancer who underwent chemotherapy and fared better than nonpregnant patients.

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not.

The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.

One research noted the persistent efforts to develop new treatments for myeloproliferative neoplasms (MPNs), a commitment that remains strong despite some setbacks.

Two nominations for the 2024 Extraordinary Healer award highlight the exceptional contributions of oncology nurses, demonstrating the power of compassionate, patient-centered care.

While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia.

A patient with MPN urges others to ask questions about treatment options, which may also include inquiring about clinical trials.